Avivagen Inc. (VIV:TSX.V; VIVXF:OTCQB) announced in a news release it entered a contract wherein INPHILCO Inc. will become a key distribution partner, distributing OxC-beta™ Livestock in the Philippines. This follows the memorandum of understanding the two companies signed in December 2019.
Manila-based INPHILCO is a veterinary company that covers poultry, swine, aquaculture, pet and feed mill requirements for animal nutrition, animal health and raw materials for compound feeds.
Per the new arrangement, INPHILCO will have the exclusive right to sell Avivagen's OxC-beta Livestock both as a component of its premixes and as a standalone product. INPHILCO will purchase OxC-beta directly from Avivagen.
"INPHILCO brings a well-earned reputation for high-quality products and deep-rooted relationships with both large integrated feed producers and commercial farms to the table, which will set the stage for increased OxC-beta Livestock use for both swine and poultry in this very important region," Avivagen CEO Kym Anthony said in the release.
The feed market in the Philippines is growing rapidly. Annual feed production there in 2020 is an estimated 18.2 million metric tons, Avivagen noted.
Read what other experts are saying about:
1) Doresa Banning compiled this article for Streetwise Reports LLC and provides services to Streetwise Reports as an independent contractor. She or members of her household own securities of the following companies mentioned in the article: None. She or members of her household are paid by the following companies mentioned in this article: None.
2) The following company mentioned in this article is a billboard sponsor of Streetwise Reports: Avivagen. Click here for important disclosures about sponsor fees.
3) Comments and opinions expressed are those of the specific experts and not of Streetwise Reports or its officers. The information provided above is for informational purposes only and is not a recommendation to buy or sell any security.
5) From time to time, Streetwise Reports LLC and its directors, officers, employees or members of their families, as well as persons interviewed for articles and interviews on the site, may have a long or short position in securities mentioned. Directors, officers, employees or members of their immediate families are prohibited from making purchases and/or sales of those securities in the open market or otherwise from the time of the interview or the decision to write an article until three business days after the publication of the interview or article. The foregoing prohibition does not apply to articles that in substance only restate previously published company releases. As of the date of this article, officers and/or employees of Streetwise Reports LLC (including members of their household) own securities of Avivagen, a company mentioned in this article.